Cite
Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure.
MLA
Harel, Stéphanie, et al. “Outcome of Patients with High Risk Myelodysplastic Syndrome (MDS) and Advanced Chronic Myelomonocytic Leukemia (CMML) Treated with Decitabine after Azacitidine Failure.” Leukemia Research, vol. 39, no. 5, May 2015, pp. 501–04. EBSCOhost, https://doi.org/10.1016/j.leukres.2015.02.004.
APA
Harel, S., Cherait, A., Berthon, C., Willekens, C., Park, S., Rigal, M., Brechignac, S., Thépot, S., Quesnel, B., Gardin, C., Adès, L., Fenaux, P., & Braun, T. (2015). Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure. Leukemia Research, 39(5), 501–504. https://doi.org/10.1016/j.leukres.2015.02.004
Chicago
Harel, Stéphanie, Amina Cherait, Céline Berthon, Christophe Willekens, Sophie Park, Marthe Rigal, Sabine Brechignac, et al. 2015. “Outcome of Patients with High Risk Myelodysplastic Syndrome (MDS) and Advanced Chronic Myelomonocytic Leukemia (CMML) Treated with Decitabine after Azacitidine Failure.” Leukemia Research 39 (5): 501–4. doi:10.1016/j.leukres.2015.02.004.